Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Natividad Viguria, Ana Navascués, Regina Juanbeltz, Alberto Echeverría, Carmen Ezpeleta & Jesús Castilla. (2021) Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Human Vaccines & Immunotherapeutics 17:6, pages 1867-1872.
Read now
Read now
Max Beugeling, Jildou De Zee, Herman J. Woerdenbag, Henderik W. Frijlink, Jan C. Wilschut & Wouter L.J. Hinrichs. (2019) Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly. Expert Review of Vaccines 18:9, pages 935-950.
Read now
Read now
Articles from other publishers (23)
Douglas Fraser-Pitt, Derry K. Mercer, Marie-Louise Francis, David Toledo-Aparicio, Daniel W. Smith & Deborah A. O'Neil. (2023) Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection. Biochemical and Biophysical Research Communications 677, pages 168-181.
Crossref
Crossref
Eilish Moore & Mary Hughes. (2023) Respiratory syncytial virus and its prophylaxis with palivizumab: exploring nurses’ knowledge. Nursing Children and Young People 35:5, pages 14-21.
Crossref
Crossref
John Fullarton, Ian Keary, Bosco Paes, Jean-Eric Tarride, Xavier Carbonell-Estrany & Barry Rodgers-Gray. (2023) Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants. The Journal of Infectious Diseases 227:11, pages 1333-1334.
Crossref
Crossref
Tingting Sun, Yingdan Wang, Peng Zou, Qimin Wang, Jiangyan Liu, Wanli Liu, Jinghe Huang & Fan Wu. (2023) M2e‐specific antibodies protect against influenza PR8 virus in an isotype and route dependent manner. Journal of Medical Virology 95:4.
Crossref
Crossref
Chee Mun Chan, Asrul Abdul Wahab & Adli Ali. (2023) Determining the Relationship of Meteorological Factors and Severe Pediatric Respiratory Syncytial Virus (RSV) Infection in Central Peninsular Malaysia. International Journal of Environmental Research and Public Health 20:3, pages 1848.
Crossref
Crossref
Paolo Manzoni, Eugenio Baraldi, Manuel Sánchez Luna & Chryssoula Tzialla. (2022) Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab. American Journal of Perinatology 39:S 01, pages S7-S13.
Crossref
Crossref
Clara Galvis, Alejandro Colmenares, Lina Cabrales, Linda Ibatá, Juliana Marulanda, Oscar Ovalle, Dionisio Puello, Catherine Rojas, Martha Africano, Adriana Ballesteros & Héctor Posso. (2022) Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals. Pediatric Pulmonology 57:10, pages 2420-2427.
Crossref
Crossref
José M. Pérez de la Lastra, Uttpal Anand, Sergio González-Acosta, Manuel R. López, Abhijit Dey, Elza Bontempi & Antonio Morales delaNuez. (2022) Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?. Frontiers in Immunology 13.
Crossref
Crossref
Susanna Esposito, Bahaa Abu Raya, Eugenio Baraldi, Katie Flanagan, Federico Martinon Torres, Maria Tsolia & Stefan Zielen. (2022) RSV Prevention in All Infants: Which Is the Most Preferable Strategy?. Frontiers in Immunology 13.
Crossref
Crossref
Ania Zylbersztejn, Ofran Almossawi, Nikesh Gudka, Daniel Tompsett, Bianca De Stavola, Joseph F. Standing, Rosalind Smyth & Pia Hardelid. (2021) Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals. British Journal of Clinical Pharmacology 88:3, pages 1246-1257.
Crossref
Crossref
Derry K Mercer, Marie-Louise FrancisDouglas Fraser-Pitt. (2021) Antimicrobial immunotherapeutics: past, present and future. Emerging Topics in Life Sciences 5:5, pages 609-628.
Crossref
Crossref
Changhao Zhang, Yan Kong & Kunling Shen. (2021) The Age, Sex, and Geographical Distribution of Self-Reported Asthma Triggers on Children With Asthma in China. Frontiers in Pediatrics 9.
Crossref
Crossref
Bosco Paes, Abby Li, Doyoung Kim, Krista L. Lanctot & Ian Mitchell. (2020) A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab. American Journal of Perinatology 38:S 01, pages e129-e136.
Crossref
Crossref
Caroline M. Sierra, Alice Park, Eunsi Eum, Giselle Garcia, Mireya Lopez, Shawnée N. Daniel, Khaled Bahjri & Kristine A. Parbuoni. (2020) Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations. Pediatric Pulmonology 56:5, pages 1121-1126.
Crossref
Crossref
Michal Young & Lynn Smitherman. (2021) Socioeconomic Impact of RSV Hospitalization. Infectious Diseases and Therapy 10:S1, pages 35-45.
Crossref
Crossref
Pilar Mendoza, Julio C.C. Lorenzi & Christian Gaebler. (2021) COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. Current Opinion in HIV and AIDS 16:1, pages 25-35.
Crossref
Crossref
Derry K. Mercer & Deborah A. O'Neil. (2020) Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response. Frontiers in Immunology 11.
Crossref
Crossref
Bindumadhav M. Marathe, Guha Asthagiri Arunkumar, Peter Vogel, Philippe Noriel Q. Pascua, Jeremy Jones, Richard J. Webby, Florian Krammer & Elena A. Govorkova. (2020) Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrobial Agents and Chemotherapy 64:9.
Crossref
Crossref
Bosco A. Paes, Mahwesh Saleem, Abby Li, Krista L. Lanctôt & Ian Mitchell. (2020) Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children. Pediatric Infectious Disease Journal 39:6, pages 539-545.
Crossref
Crossref
Gabriel Rainisch, Bishwa Adhikari, Martin I. Meltzer & Gayle Langley. (2020) Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants. Vaccine 38:2, pages 251-257.
Crossref
Crossref
Lydia J. Atherton, Patricia A. Jorquera, Abhijeet A. Bakre & Ralph A. Tripp. (2019) Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. Frontiers in Immunology 10.
Crossref
Crossref
Bosco Paes, Mahwesh Saleem, Doyoung Kim, Krista L. Lanctôt & Ian Mitchell. (2019) Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab. European Journal of Clinical Microbiology & Infectious Diseases 38:8, pages 1561-1568.
Crossref
Crossref
Hadi Abou-El-Hassan, Elie Massaad, Nadia Soudani, Aia Assaf-Casals, Rouba Shaker, Mireille Lteif Khoury, Soha Ghanem, Maria Karam, Rabih Andary, Reiko Saito, Ghassan Dbaibo & Hassan Zaraket. (2019) Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon. PLOS ONE 14:2, pages e0212687.
Crossref
Crossref